These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32713439)

  • 101. ASO Author Reflections: Postoperative Chemotherapy After Neoadjuvant Therapy and Pancreatectomy for Pancreatic Cancer: Balancing Patient Physiology and Disease Biology.
    Kamarajah SK; Dahdaleh F
    Ann Surg Oncol; 2021 Oct; 28(11):6803-6804. PubMed ID: 33774772
    [No Abstract]   [Full Text] [Related]  

  • 102. Total Neoadjuvant Therapy for Pancreatic Cancer-What Is Totality?
    Cannas S; Vollmer CM
    JAMA Surg; 2024 Jul; 159(7):828-829. PubMed ID: 38656533
    [TBL] [Abstract][Full Text] [Related]  

  • 103. A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma.
    Fraunhoffer N; Chanez B; Teyssedou C; ; Iovanna JL; Mitry E; Dusetti NJ
    Gastroenterology; 2023 Mar; 164(3):476-480.e4. PubMed ID: 36496056
    [No Abstract]   [Full Text] [Related]  

  • 104. Borderline resectable pancreatic cancer: what have we learned and where do we go from here?
    Katz MH; Pisters PW; Lee JE; Fleming JB
    Ann Surg Oncol; 2011 Mar; 18(3):608-10. PubMed ID: 21136179
    [No Abstract]   [Full Text] [Related]  

  • 105. Impact of biliary intervention rates during neoadjuvant therapy for pancreatic head adenocarcinoma.
    Varshney VK; Swami A
    HPB (Oxford); 2021 Apr; 23(4):644. PubMed ID: 33573878
    [No Abstract]   [Full Text] [Related]  

  • 106. Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten. Letter to the Editor regarding: "Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up" by Huguet et al.
    Huguet F; Bouchart C; Bruynzeel AME; Hawkins MA; Mukherjee S; Nuyttens JJ; Riou O; Scorsetti M; Versteijne E; Loi M; Vendrely V
    Ann Oncol; 2024 Aug; 35(8):749-750. PubMed ID: 39048262
    [No Abstract]   [Full Text] [Related]  

  • 107. Reply to the Letter to the Editor 'Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten' (in regard to "Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up") by Huguet et al.
    Conroy T; Haustermans K; Ducreux M;
    Ann Oncol; 2024 Aug; 35(8):750-751. PubMed ID: 39048263
    [No Abstract]   [Full Text] [Related]  

  • 108. Finding the tumor copycat. Therapy fails, patients don't.
    Ellis LM; Fidler IJ
    Nat Med; 2010 Sep; 16(9):974-5. PubMed ID: 20823880
    [No Abstract]   [Full Text] [Related]  

  • 109. Identification of tumour regression in neoadjuvantly treated pancreatic cancer is based on divergent and nonspecific criteria.
    Holm MB; Lenggenhager D; Detlefsen S; Sántha P; Verbeke CS
    Histopathology; 2024 Jul; 85(1):171-181. PubMed ID: 38571446
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Comments regarding "Neoadjuvant Therapy Versus Upfront Resection for Nonpancreatic Periampullary Adenocarcinoma".
    Nicolson NG; He J
    Ann Surg Oncol; 2023 Feb; 30(2):1221-1222. PubMed ID: 36463353
    [No Abstract]   [Full Text] [Related]  

  • 111. [Systemic chemotherapy for metastatic pancreatic cancer].
    Morizane C
    Nihon Shokakibyo Gakkai Zasshi; 2023; 120(8):651-657. PubMed ID: 37558411
    [No Abstract]   [Full Text] [Related]  

  • 112. Reply to the Letter from Norman G. Nicolson and Jin He on Our Publication "Neoadjuvant Therapy Versus Upfront Resection for Nonpancreatic Periampullary Adenocarcinoma".
    Adam MA; AlMasri S; Glencer A; Zureikat AH
    Ann Surg Oncol; 2023 Feb; 30(2):1223-1224. PubMed ID: 36479661
    [No Abstract]   [Full Text] [Related]  

  • 113. Mouse Models to Study Secondary Cancer Prevention.
    Li L; Chandra V; McAllister F; Zhang Y
    Methods Mol Biol; 2022; 2435():215-223. PubMed ID: 34993950
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Conversion of locally advanced to resectable pancreatic body cancer aided by phosphorus-32 brachytherapy (OncoSil).
    Welsh F; Goodwin B; Lanka L; Allen B; Wong J; Weilert F
    N Z Med J; 2023 Feb; 136(1570):78-80. PubMed ID: 36796322
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma.
    Link JM; Liudahl SM; Betts CB; Sivagnanam S; Leis KR; McDonnell M; Pelz CR; Johnson B; Hamman KJ; Keith D; Sampson JE; Morgan TK; Lopez CD; Coussens LM; Sears RC
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036232
    [No Abstract]   [Full Text] [Related]  

  • 116. Small steps can lead to substantial breakthroughs: moving the therapeutic needle forward in pancreatic cancer.
    Pathak P; Weekes C; Wo JY
    Lancet Oncol; 2024 Jul; 25(7):824-825. PubMed ID: 38834088
    [No Abstract]   [Full Text] [Related]  

  • 117. ASO Author Reflections: Neoadjuvant Therapy for Ampullary and Duodenal Adenocarcinoma-What Do We Know?
    Zhang C; Reames BN
    Ann Surg Oncol; 2024 Feb; 31(2):808-809. PubMed ID: 37993747
    [No Abstract]   [Full Text] [Related]  

  • 118. Neoadjuvant Treatment and Surgical Resection Are Associated with Survival in Pancreatic Cancer.
    He J; Schmocker R
    J Am Coll Surg; 2021 Jun; 232(6):1023-1024. PubMed ID: 33722461
    [No Abstract]   [Full Text] [Related]  

  • 119. Comments on "Importance of Normalization of CA19-9 Levels After Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer".
    Xu HX; Li S; Xu SS; Liu L; Yu XJ
    Ann Surg; 2021 Dec; 274(6):e800-e801. PubMed ID: 33065647
    [No Abstract]   [Full Text] [Related]  

  • 120. Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients.
    Gyawali B; Booth CM
    Lancet Oncol; 2024 Feb; 25(2):167-170. PubMed ID: 38301687
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.